ATXI

Avenue Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website avenuetx.com
Employees(FY) 2
ISIN US05360L4032

Performance

-1.23%

-4.74%

-31.16%

-46.11%

-83.35%

YTD

-86.67%

Profile

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.

Advanced Technical Analysis

Technical Analysis of ATXI 2024-11-20

The stock's Moving Average Score of 10 indicates a strong bearish sentiment, while the Oscillators Score of 50 reflects a neutral stance. Overall, the combined Technical Score of 30 reinforces a bearish outlook, suggesting caution for potential investors.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ATXI

Stock Rank

Recent News & Updates

2024-11-14 03:05
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights(Globenewswire)
2024-10-08 20:30
Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit(Globenewswire)
2024-09-02 20:30
Avenue Therapeutics to Participate in Upcoming Investor Conferences(Globenewswire)
2024-08-13 04:05
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights(Globenewswire)
2024-08-09 08:53
ATXI Stock Earnings: Avenue Therapeutics Misses EPS for Q2 2024(Investorplace)
2024-08-09 04:05
Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights(Globenewswire)
2024-06-19 20:30
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference(Globenewswire)
2024-05-15 20:30
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)(Globenewswire)
2024-05-15 09:55
ATXI Stock Earnings: Avenue Therapeutics Misses EPS for Q1 2024(Investorplace)
2024-05-14 20:30
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights(Globenewswire)
2024-04-28 20:00
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds(Globenewswire)
2024-04-23 19:30
Avenue Therapeutics Announces Reverse Stock Split(Globenewswire)
2024-03-24 20:30
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024(Globenewswire)
2024-03-18 18:53
ATXI Stock Earnings: Avenue Therapeutics Beats EPS for Q4 2023(Investorplace)
2024-03-18 04:05
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights(Globenewswire)
2024-03-14 20:15
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq(Globenewswire)
2024-03-10 20:00
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting(Globenewswire)
2024-02-21 19:30
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy(Globenewswire)
2024-01-15 19:40
Sidoti Events, LLC's Virtual January Micro-Cap Conference(Yahoo Finance)
2024-01-10 19:00
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference(Globenewswire)
2024-01-04 20:15
Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds(Globenewswire)
2024-01-03 19:30
Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol(Globenewswire)
2024-01-01 19:30
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)(Globenewswire)
2023-11-30 19:30
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting(Globenewswire)
2023-11-28 19:05
Why Is Avenue Therapeutics (ATXI) Stock Up 59% Today?(Investorplace)
2023-11-13 03:05
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights(Globenewswire)
2023-11-02 03:00
Avenue Therapeutics Announces Closing of $5.0 Million Public Offering(Globenewswire)
2023-10-30 21:15
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering(Globenewswire)
2023-09-04 20:30
Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference(Yahoo Finance)
2023-08-14 04:01
Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights(Yahoo Finance)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.